AI Article Synopsis
- - Sarcoma refers to a variety of cancers that develop in soft tissue or bone, showing significant differences in behavior and treatment responses despite their histologic classifications.
- - Advances in genetic sequencing have unveiled new genetic targets for therapy, leading to the development of treatments that focus on specific mutations and alterations in sarcoma cells.
- - Although soft tissue sarcomas generally have a poor prognosis, emerging targeted therapies and immunotherapies are offering more effective treatments with reduced side effects.
Article Abstract
Sarcoma is a broad term for mesenchymal malignancies that arise from soft tissue or bone. Despite classification by histologic subtype, clinical behavior and response to therapy have great variability. Modern genetic sequencing techniques have been able to identify additional genetic variability and subsequently new targeted therapies. In this review, we discuss the current state of STS diagnostics and treatment and explore some of the more promising areas in which progress is being made. We discuss therapies targeting PDGFRα/KIT, β-Catenin/APC/NOTCH, IDH-1/2 mutations, MDM2 amplifications, EZH2/INI1 expression loss, ALK fusion, and ASPSCR1-TFE3 fusion. We also discuss the progress that has been made within immunotherapies. While soft tissue sarcomas still portend a poor prognosis, these targeted therapies and immunotherapies provide treatment with less toxic side effects.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.currproblcancer.2019.06.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!